Medtronic Enterra HDE Status Hinders Reimbursement – Disease Group
This article was originally published in The Gray Sheet
Executive Summary
Published efficacy data on Medtronic's Enterra Therapy device for drug-refractory gastroparesis are sufficient to justify accelerated PMA approval, according to a recent petition filed with FDA by the Gastroparesis & Dysmotilities Association (GPDA)